# OneThree Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onethree-biotech

- Industry: Software
- Headquarters: New York, US
- Website: www.onethree.bio
- Total disclosed funding: $2.5M
- Latest round: Seed (Mar 26, 2020)
- Investors on record: 2

## About

OneThree Biotech is a biotechnology company focused on developing innovative biotherapeutics and agricultural solutions to enhance health and agricultural productivity. Their efforts leverage synthetic biology to address critical challenges in these sectors.OneThree Biotech, founded in 2018, operates out of New York, US. The company specializes in biotechnology solutions and has raised a total of USD 2.5 mn in Seed funding, led by Meridian Street Capital and Primary Venture Partners in March 2020. The founders, Brad Pryde and Neel Madhukar, have a background in developing technology-driven health solutions.OneThree Bio specializes in developing innovative solutions that harness the power of biotechnology to address critical challenges in human health and agriculture. The company's core offerings include advanced biotherapeutics and agricultural solutions that leverage synthetic biology to enhance the efficacy of treatments and improve crop resilience. These products aim to solve pressing problems such as the need for more effective therapies for chronic diseases and the increasing demand for sustainable agricultural practices. The company serves a diverse client base that includes pharmaceutical companies, research institutions, and agricultural enterprises across North America, Europe, and Asia. By focusing on these markets, OneThree Bio positions itself as a leader in the integration of biotechnology across various sectors, aiming to promote healthier lives and a more sustainable environment.OneThree Bio generates revenue primarily through partnerships and collaborations with various stakeholders in the pharmaceutical and agricultural industries. The company engages in B2B transactions where it offers its biotherapeutic and agricultural products to pharmaceutical firms and agricultural distributors. These transactions typically involve agreements that may include milestone payments tied to research and development progress, as well as revenue-sharing arrangements based on product sales. OneThree Bio's flagship products are designed to meet specific market needs, and the company’s pricing structure is crafted to reflect the value and innovation brought to its partners. Through these strategic collaborations and offerings, OneThree Bio establishes a robust revenue model that aligns with the continual advancement of biotechnological applications.OneThree Biotech plans to utilize the USD 2.5 mn raised in its Seed funding round to accelerate the development of new biotherapeutic products aimed at addressing chronic diseases and enhancing agricultural resilience. They are targeting expansions into key markets in Europe and Asia by 2023, focusing on strategic partnerships to facilitate entry. The company aims to launch several new products within the next 18 months that leverage synthetic biology advancements to meet emerging health and agricultural needs.

## Funding rounds

- Seed, Mar 26, 2020, $2.5M — Primary Venture Partners, Meridian Street Capital

## Investors

- Primary Venture Partners (https://capitalatlas.ai/funds/primary-venture-partners) — Seed
- Meridian Street Capital (https://capitalatlas.ai/funds/meridian-street-capital) — Seed